Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01337752 · ClinicalTrials.gov registry record · Phase 2
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01337752: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT01337752 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01337752, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy. The primary objective of the study will be to evaluate the effect of BHQ880 in combination with bortezomib and dexamethasone, compared to placebo administered with the combination on the time to first Skeletal Related Event (SRE) on study.
Primary Outcome
Time to first SRE from randomization
Interventions
- DRUG dexamethasone
- DRUG bortezomib
- DRUG BHQ880
- DRUG BHQ880 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
What the finished NCT01337752 record still lists
NCT01337752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 4 interventions - of which dexamethasone is the first listed.
NCT01337752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01337752 about?
NCT01337752 is a clinical study titled "Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency". The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy. The primary objective of the study will be to evaluate the effect of BHQ880 in combination with bortezomib and de...
What is the current status of trial NCT01337752?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2012-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01337752?
The interventions under investigation include: dexamethasone (DRUG), bortezomib (DRUG), BHQ880 (DRUG), BHQ880 Placebo (DRUG).
Who is sponsoring clinical trial NCT01337752?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01337752's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia